CheckMate 171: Phase 2 trial of nivolumab for advanced squamous cell non-small cell lung cancer

Updates from CheckMate 017 and CheckMate 057: Nivolumab, anti-PD1, for non-small cell lung cancerПодробнее

Subgroup benefits identified in RELATIVITY-104 for advanced non-small cell lung cancerПодробнее

Comment: Nivolumab plus ipilimumab combination for advanced NSCLCПодробнее

Checkmate 9LA: Nivolumab, ipilimumab and chemotherapy for stage IV NSCLCПодробнее

Dr. Spigel on CheckMate-331 Trial for SCLCПодробнее

Dr. Spigel on Checkmate 017- Phase III Trial for Nivolumab - Sarah CannonПодробнее

Update from CheckMate 057: Nivolumab versus docetaxel in advanced non-squamous NSCLCПодробнее

29-month follow-up from CheckMate 648: nivolumab combination therapy in ESCCПодробнее

Long-term efficacy of nivolumab combinations in advanced ESCC in CheckMate 648Подробнее

CheckMate 648: Novel treatment for patients with advanced esophageal squamous cell carcinomaПодробнее

Advanced NSCLC: Refining Clinical Pathways in the Rapidly Evolving Therapeutic LandscapeПодробнее

Quality of life and symptom control for non-squamous NSCLC patients on nivolumab (CheckMate 057)Подробнее

Adverse Events of Nivolumab in Patients With Advanced, Non-Squamous NSCLCПодробнее

CheckMate 172 trial of nivolumab for advanced melanoma: preliminary resultsПодробнее

Immunotherapy for Squamous Non-Small Cell Lung CancerПодробнее

CheckMate 9LA study: nivo + ipi in NSCLCПодробнее

The CheckMate 9LA Trial for Stage IV/Recurrent Non-Small Cell Lung CancerПодробнее

SQUINT: nivolumab+ipilimumabi v platinum-based CT+nivolumab in advanced lung squamous cell carcinomaПодробнее

CheckMate 9LA Trial on Nivolumab plus Ipilimumab for NSCLCПодробнее